Edgewise Therapeutics, Inc. (EWTX)
- Previous Close
17.48 - Open
17.48 - Bid 17.18 x 100
- Ask 17.33 x 100
- Day's Range
17.18 - 17.91 - 52 Week Range
5.12 - 21.60 - Volume
442,792 - Avg. Volume
745,013 - Market Cap (intraday)
1.609B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.54 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.00
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
www.edgewisetx.comRecent News: EWTX
Performance Overview: EWTX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EWTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EWTX
Valuation Measures
Market Cap
1.63B
Enterprise Value
1.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.05
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.14%
Return on Equity (ttm)
-24.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-105.85M
Diluted EPS (ttm)
-1.54
Balance Sheet and Cash Flow
Total Cash (mrq)
532.76M
Total Debt/Equity (mrq)
0.98%
Levered Free Cash Flow (ttm)
-59.75M
Research Analysis: EWTX
Company Insights: EWTX
EWTX does not have Company Insights